Leukemic presentation of ALK+ Anaplastic Large Cell Lymphoma with a novel partner, poly(A) binding protein cytoplasmic 1 (PABPC1), responding to single-agent crizotinib


Disclosures: none

Contributions: DG, KC, AH, and HI treated the patient, provided clinical information and contributed to the writing of the manuscript; LA interpreted WGS, WES, and RNA-seq data; RKS and CGM contributed reagents assisted in preparation of the manuscript; JM performed experiments; SR and MV performed and analyzed cytogenetic and FISH data; and VL designed experiments, interpreted data, and wrote the manuscript.